BCR and cancer: The most well-documented aggressive subtypes are intraductal carcinoma of the prostate and tumors with cribriform architecture, both of which are associated with decreased time to BCR, increased presence of ECE, increased metastatic potential, and shorter cancer-specific mortality (129).